Celsion Corporation (CLSN)

[Biobonic]

No, not a fail. It keeps going.

The upcoming second interim review:

So to be clear, I'll say it another way. The bar for success is lower than what we have seen in the prospective HEAT Study subgroup analyses. So as I said and I'll say it again, I remain very optimistic that we have a much better chance for success at the upcoming second interim analysis following the DMC's review.

Now if the study does not meet the standard for success at 158 deaths, we uniquely have another opportunity, a third bite of the apple if you will. We have a final [indiscernible] data following 197 patient deaths. At this point the bar will be much lower. The p value and hazard ration required for positive trial at the final analysis are 0.043 and 0.75 respectively, which is even further below the valance observed in the prospective HEAT Study subgroup and certainly bodes well for successful trial.

I'm not risking a lot in this,...